Cytokines and Brain-Derived Neurotrophic Factor as Biomarkers of Cognitive Impairment Related to Breast Cancer and Its Treatments: A Systematic Review
Authors:
- Yenny Trinidad Fierro-SalgadoYFYenny Trinidad Fierro-Salgado
- Manuel ReirizMRManuel Reiriz
- Ana Isabel Beltrán-VelascoAna Isabel Beltrán-Velasco
- Javier Calleja-CondeJCJavier Calleja-Conde
- Xabier Hernández-OñativiaXHXabier Hernández-Oñativia
- Sara UcedaSUSara Uceda
- Víctor Echeverry-AlzateVíctor Echeverry-Alzate
Open Access
- 16 October 2025
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (20) , 10074
Abstract
Breast cancer is a globally prevalent oncological disease whose treatments, while improving survival rates, often lead to adverse cognitive effects. Brain-derived neurotrophic factor (BDNF) and cytokines, key mediators of the inflammatory response, may play a significant role in these cognitive alterations. This systematic review (osf.io/vk37x) addresses the use of BDNF and cytokines as biomarkers of cognitive impairment in breast cancer animal models. A comprehensive literature search was conducted across the following databases: Web of Science, Scopus, ScienceDirect, PubMed, and Medline. Keywords used were: (“breast cancer” AND “cognitive impairment” AND (“brain derived neurotrophic factor” OR “cytokines”). A total of 9876 articles were identified, of which 17 studies met the inclusion criteria. For quality assessment the SYRCLE’s tool for assessing Risk of Bias was used. Neuroinflammatory and systemic inflammatory responses, particularly increases in pro-inflammatory cytokines (IL-6, IL-1β, TNF-α) and reductions in hippocampal BDNF, are consistently linked to breast cancer and chemotherapy-induced cognitive impairment in animal models. Several interventions normalized these biomarkers and improved cognitive performance after chemotherapy. Anti-inflammatory cytokines (IL-10 or IL-4) were measured in fewer studies and recent research suggests that they could serve as potential protective biomarkers. BDNF, pro- and anti-inflammatory cytokines may represent candidate biomarkers for cancer-related cognitive impairment.Keywords
This publication has 118 references indexed in Scilit:
- Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancerCochrane Database of Systematic Reviews, 2020
- Therapeutic Potentials of BDNF/TrkB in Breast Cancer; Current Status and PerspectivesJournal of Cellular Biochemistry, 2017
- Effect of aerobic exercise on cancer‐associated cognitive impairment: A proof‐of‐concept RCTPsycho-Oncology, 2017
- Cytokine‐mediated blood brain barrier disruption as a conduit for cancer/chemotherapy‐associated neurotoxicity and cognitive dysfunctionInternational Journal of Cancer, 2016
- Surgical treatment of primary breast cancer in the neoadjuvant settingBritish Journal of Surgery, 2014
- Tibetan sound meditation for cognitive dysfunction: results of a randomized controlled pilot trialPsycho-Oncology, 2013
- Self‐reported cognitive functioning in postmenopausal breast cancer patients before and during endocrine treatment: findings from the neuropsychological TEAM side‐studyPsycho-Oncology, 2011
- Development of CBT for chemotherapy‐related cognitive change: results of a waitlist control trialPsycho-Oncology, 2010
- The effect of modafinil on cognitive function in breast cancer survivorsCancer, 2009
- Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancerPsycho-Oncology, 1995